Aqua Bio Technology (ABTEC) Q3 2025 earnings summary

Executive summary

• Q3 2025 marked by ongoing restructuring, divestments, and focus on financial stability for future growth.

• Three business areas: skincare ingredients, product sales/distribution, and logistics via Jetcarrier AS.

• Sale of Cosmed Beauty AS and Ultrabody AB in Q4 2025 as part of restructuring.

• Correction of prior consolidation error for Jetcarrier; now treated as a financial investment.

• New CEO & CFO appointed August 2025; focus on cost minimization and operational efficiency.

Financial highlights

• Q3 2025 revenue: NOK 6.9m (Q3 2024: NOK 6.5m); NOK 5.0m from a settlement agreement.

• Q3 2025 EBITDA: NOK -0.8m (Q3 2024: NOK -68.6m); operating loss: NOK -1.4m (Q3 2024: NOK -70.0m).

• Net result from continuing operations Q3 2025: NOK -5.1m (Q3 2024: NOK -73.2m).

• 9M 2025 revenue: NOK 14.4m (9M 2024: NOK 20.0m); 9M EBITDA: NOK -10.2m (9M 2024: NOK -84.0m).

• Net result from discontinued operations 9M 2025: NOK 125.9m, reflecting gains from divestments and debt derecognition.

Outlook and guidance

• Activity and revenue in continuing operations remain low; focus on market segments expected to create new growth opportunities from 2026.

• Jetcarrier expected to drive growth and profitability from 2026 despite current non-consolidation.

• Ongoing efforts to secure both short- and long-term financing; multiple strategic options under consideration.